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Hepatic encephalopathy in a hospitalized cirrhotic patient is
associated with a high mortality rate and its presence adds
further to the mortality of patients with acute-on-chronic liver
failure (ACLF). The exact pathophysiological mechanisms of HE
in this group of patients are unclear but hyperammonemia,
systemic inﬂammation (including sepsis, bacterial translocation,
and insulin resistance) and oxidative stress, modulated by gluta-
minase gene alteration, remain as key factors. Moreover, alcohol
misuse, hyponatremia, renal insufﬁciency, and microbiota are
actively explored. HE diagnosis requires exclusion of other causes
of neurological, metabolic and psychiatric dysfunction. Hospital-
ization in the ICU should be considered in every patient with
overt HE, but particularly if this is associated with ACLF. Precipi-
tating factors should be identiﬁed and treated as required.
Evidence-based speciﬁc management options are limited to
bowel cleansing and non-absorbable antibiotics. Ammonia
lowering drugs, such as glycerol phenylbutyrate and ornithine
phenylacetate show promise but are still in clinical trials.
Albumin dialysis may be useful in refractory cases. Antibiotics,
prebiotics, and treatment of diabetes reduce systemic inﬂamma-
tion. Where possible and not contraindicated, large portal-
systemic shunts may be embolized but liver transplantation is
the most deﬁnitive step in the management of HE in this setting.
HE in patients with ACLF appears to be clinically and pathophys-
iologically distinct from that of acute decompensation and
requires further studies and characterization.Journal of Hepatology 20
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Hepatic encephalopathy (HE) is a major complication of liver
cirrhosis, affecting up to one third of cirrhotic patients and is
classiﬁed into three types: Type A HE is due to acute liver fail-
ure (ALF); type B HE is due to portal-systemic shunting without
intrinsic liver disease; and type C HE occurs in patients with
underlying cirrhosis [1]. HE manifests as a spectrum, ranging
from minimal disturbances in mental function that impact on
attention, cognition and quality of life to coma. In this review,
patients with type C HE who require hospital admission will
be discussed.
Using the Clinical Practice Research Datalink in the UK, the
presence of HE in hospitalized cirrhotics was associated with
signiﬁcantly higher mortality [2]. In the USA, between 2005
and 2009, the incidence of new patients hospitalized due to
hepatic encephalopathy slightly increased and showed more
severe disease, expanding resource utilization and keeping mor-
tality stable [3]. Recent prospective studies, evaluating the
natural history of hospitalized cirrhotic patients, have started
to provide new information about the prevalence and outcome
of HE [4]. Of the 1348 patients studied, 460 had varying grades
of HE (34%): 43% died within 1-year and the short-term mortal-
ity rate was signiﬁcantly higher in patients with more advanced
grades of HE. The subgroup of patients with high short-term
mortality and organ failures had a higher mortality. This patient
group was referred to as acute-on-chronic liver failure (ACLF)
[5]. An important new concept that has emerged is that the
presence of HE with or without ACLF is associated with a
signiﬁcantly worse outcome compared with non-HE patients
[6]. The data indicate that HE independently of other organ fail-
ures adds signiﬁcantly to the risk of death (Fig. 1). Moreover, in
a prospective cohort from NACSELD (North American Consor-
tium for study of end-stage liver disease), including 507
hospitalized decompensated infected cirrhosis patients, hepatic
encephalopathy grade 3/4 was the most commonly detected
organ failure and the number of organs inﬂuenced survival [7].15 vol. 62 j 437–447
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Fig. 1. Actuarial survival curve of hospitalized cirrhotic patients showing
mortality of patients with or without ACLF in combination of with or without
overt hepatic encephalopathy.Mortality rate was signiﬁcantly higher in patients
with ACLF and HE in comparison with non-HE patients with ACLF. In decom-
pensated cirrhosis HE was also related to a raised mortality. Adapted from
Cordoba J. et al. [6].
ReviewKey Points
• Interorgan ammonia trafficking, systemic inflammation 
and oxidative stress, modulated by glutaminase gene 
alteration, are key factors in the pathophysiology of 
hepatic encephalopathy (HE)
• HE in acute-on-chronic liver failure (ACLF) 
patients is distinct clinically, prognostically and 
pathophysiologically to the conventional forms 
represented in type A, B and C of HE
• Management of HE in hospitalized patients requires 
admission to the ICU when the Glasgow Coma scale 
is less than 8. Precipitating factors should be identified 
and treated. Specific measures should be focused 
on decreasing hyperammonemia and systemic 
inflammatory response. Albumin dialysis and 
embolization of portosystemic shunts could rescue 
refractory patients
• Hepatic encephalopathy in critically ill, hospitalized 
cirrhotic patients should be considered a high priority 
criteria for liver transplantation. However, at present 
there is no priority for severe HE patients on the 
waiting listPathophysiology of hepatic encephalopathy in hospitalized
patients
The pathophysiology of HE is multifactorial and complex but
hyperammonemia, systemic inﬂammation and genetic factors
are thought to be important. There are no human neuropathologic
data but electron microscopic studies in animal models of ACLF
show that the astrocytes are swollen with markedly vasocon-
stricted blood vessels [8]. Increased intracranial pressure is
common in patients with ALF. In patients with ACLF, an overt
increase in intracranial pressure and cerebral oedema-related
deaths have been described in small case series [9,10]. More
recently, a retrospective study suggested that overt cerebral
oedema was observed in about 5% patients with ACLF [11], which
was conﬁrmed by imaging studies [12]. Therefore, although brain438 Journal of Hepatology 201swelling is a feature of ACLF, the relatively low incidence of deaths
from cerebral herniation may be related to cerebral atrophy or
reduced cerebral perfusion, which are known features of cirrhosis
and HE [13].
Hyperammonemia
In the brain, astrocytes are the only cells that metabolize ammo-
nia by the enzyme glutamine synthetase, converting glutamate
and ammonia into glutamine. Glutamine accumulation, as an
osmolyte, promotes astrocyte swelling [14]. Ammonia also
induces oxidative, cellular stress and energy failure.
Data regarding a direct correlation between ammonia concen-
tration and the severity of HE are limited. In a systematic review,
a general correlation between higher levels of ammonia and more
severe encephalopathy in cirrhosis was observed [15]. More
recently, a retrospective study in cirrhotic patients with grade
3/4 HE showed that patients were hyperammonemic but the
absolute levels did not correlate with the severity of HE [16].
Studies in animal models have consistently shown that induction
of hyperammonemia results in brain oedema and the reduction
in ammonia translates into reduced brain swelling, ﬁrmly con-
ﬁrming the central role of ammonia as a therapeutic target
[16]. Interestingly, in a model of cirrhosis, reduction in ammonia
concentration protected the brain from a subsequent challenge
with lipopolysaccharide [17]. Thus, ammonia seems to sensitize
the brain to a secondary inﬂammatory insult.
Inﬂammation
Inﬂammatory response, infections and sepsis
The impact of the systemic inﬂammatory response on ammonia-
induced brain dysfunction was described in cirrhotic patients
admitted to the hospital with infection [18]. The main source of
inﬂammation in cirrhotics was infection and sepsis. Ammonia-
induced deterioration in neuropsychological dysfunction was
prevented by antibiotics, supporting the notion of a synergy
between ammonia and inﬂammation in the pathogenesis of HE.
Merli et al. conﬁrmed the presence of cognitive impairment
(overt or subclinical) in 42% of cirrhotics without infection, in
79% with infection and in 90% with sepsis [19]. Hung et al.
observed that infections increase the mortality of HE cirrhotic
patients, especially pneumonia and sepsis without speciﬁc focus
[20]. Lastly, in the CANONIC study described above, a clear role
for systemic inﬂammation was demonstrated in patients with
advanced HE, which correlated with mortality.
Neuroinﬂammation, hyponatremia and oxidative stress
Changes in the permeability of the blood-brain barrier (BBB) to
water and other small molecules [21,22] together with hypona-
tremia [23] and oxidative stress have been implicated in HE
[24]. The BBB protects from common bacterial infections or tox-
ins, and from the ﬂuctuation of plasma components and neuro-
transmitters in the blood. During infection, microglial cells (the
resident macrophages of the brain) and astrocytes may release
pro-inﬂammatory cytokines (TNFa, IL-6), which enhance neuro-
psychological impairment induced by hyperammonemia [25]
but this observation remains controversial [26,27]. Nonetheless,
TNFa levels correlate with HE severity [28] and some anti-TNFa
drugs like etanercept and inﬂiximab work on animal models of
HE. Moreover, COX-1 inhibitors and NSAIDs have been found to5 vol. 62 j 437–447
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Fig. 2. Ammonia trafﬁcking in hepatic encephalopathy (HE) from an organism (left panel) and an organ (right panel) perspective. A modiﬁed nitrogen balance and
changes in ammonia production/disposal lead to hyperammonaemia. Hyperammonaemia, together with hyponatremia, increased levels of pro-inﬂammatory cytokines, an
activated microglia and a number of other mechanisms lead to astrocyte swelling. In turn, this results in dysfunctional astrocyte-neuron interactions and, ultimately, in
neuronal dysfunction. Other neurotoxins, such as cytokines, indoles and possibly mercaptans may also affect neurons directly. Adapted from Amodio P., Hepatic
Encephalopathy in Cirrhosis: a practical guide to management [Moreau & Lee Eds, Oxford University Press (in press)].
JOURNAL OF HEPATOLOGYbe protective in animal models of HE, modulating neuroinﬂam-
mation [29,30]. However, these therapeutic approaches did not
reach applicability in humans. Precipitating factors for HE, such
as sepsis, hyponatraemia, gastrointestinal haemorrhage and renal
failure are known to share different pathophysiological mecha-
nisms beyond increasing TNFa production or COX-1 activity [31].
Hyponatremia is a major confounding factor in the patho-
physiology of HE in patients with ACLF and it could be very difﬁ-
cult to differentiate between hepatic and hyponatremic
encephalopathy. Hyperammonemia in ACLF would cause an
increased intracellular content of glutamine and osmolality, due
to glutamine synthase activity, resulting in astrocyte swelling
and astrocyte dysfunction enhanced by oxidative stress. Astro-
cyte swelling triggers a signalling cascade, increasing formation
of reactive nitrogen and oxygen species, mainly through activa-
tion of NADPH oxidase and nitric oxide synthase [32]. Reactive
nitrogen and oxygen species enhance protein tyrosine nitration,
mobilization of zinc, oxidation of RNA, alterations in intra- and
intercellular signalling and in gene transcription [33]. Whether
the brain is directly involved in the inﬂammatory process inJournal of Hepatology 201chronic liver failure or whether it is the systemic response that
spills into the brain is not clear [34,35] (Fig. 2). Lastly, hyponatre-
mia could represent a second osmotic hit to astrocytes that could
aggravate the intracellular oedema. [36]. Renal ammoniagenesis
increases during haemodynamic disturbances in cirrhotics char-
acterized by effective hypovolemia secondary to splanchnic arte-
rial vasodilation, similar to that associated with renal failure,
hyponatremia, hypokalaemia, dehydration, or use of nephrotoxic
agents, highlighting the key role of the kidneys on hepatic
encephalopathy. In a large cohort of 562 cirrhotic patients, the
main causes of renal insufﬁciency were infections, hypovolemic
conditions, hepatorenal syndrome and nephrotoxic agents. Hepa-
tic encephalopathy, hyponatremia and MELD predicted prognosis
according to the different causes of AKI [37].
Bacterial translocation (BT) and microbiome
Bacterial infections are well-known triggers for HE in patients
with cirrhosis [38]. Multifactorial damage of the intestinal barrier
results in a high rate of intestinal bacteria translocation in cirrho-
tics, resulting in systemic inﬂammation [39,40]. Therefore, BT5 vol. 62 j 437–447 439
Ammonemia 
Intestinal a nd kidney 
glutaminase activity
Intestinal bacteria
production
Inflammation 
Bacterial translocation 
Pro-inflammatory state due 
to metabolic disturbances 
(IR & T2DM) 
Liver 
dy fs un tc ion 
Porto-systemic 
hs unts 
Glutaminase gene
OXIDATIVE  AND  
NITROSATIVE STRESS 
GABA system
Microbioma Alcohol misuse
Hyponatremia
renal
insufficiency
Fig. 3. Pathophysiology of hepatic encephalopathy. Hyperammonemia, sys-
temic inﬂammation and oxidative and nitrosative stress in patients with liver
dysfunction and/or portosystemic shunts modulated by glutaminase gene
alterations are key factors and therapeutic targets on hepatic encephalopathy.
Reviewmay have a role in the pathogenic mechanisms involved in HE,
due to circulating endotoxins, which activate macrophages to
produce TNFa and other potentially cytotoxic pro-inﬂammatory
mediators [41]. Indeed, a high frequency of small-intestinal bac-
terial overgrowth (SIBO) in cirrhotic patients has been correlated
with BT [42]. On the other hand, microbiota could play a relevant
role, irrespective of bacterial translocation. The dysbiosis rate,
calculated as the ratio of autochthonous to non-autochthonous
taxa, was related to hepatic encephalopathy. Patients developing
overt HE during the follow-up demonstrated a lower rate of
dysbiosis in comparison with compensated cirrhosis. Besides,
the dysbiosis rate was associated with endotoxin levels; the
higher the endotoxemia, the lower the dysbiosis rate [43,44].
Diabetes mellitus (DM) and insulin resistance (IR)
Diabetes mellitus (DM) and insulin resistance (IR) was recently
shown to be more frequently (59% vs. 43%) associated with the
presence of HE [45], which was conﬁrmed in another study
[46]. The mechanisms underlying this may be related to
increased glutaminase activity in the kidney, liver and small
intestine [47]; increased pro-inﬂammatory cytokines such as
TNFa and IL-6, resulting in systemic inﬂammatory response
[48]; increased protein catabolism and ammonia production
[49] act upon the role of insulin to stimulate protein synthesis
as well as on the inhibition of protein degradation; and a reduc-
tion in duodenum-cecal transit time due to autonomic neuropa-
thy, resulting in constipation and SIBO [50].
Alcohol misuse
The CANONIC study demonstrated alcohol misuse was strongly
related to HE in younger patients with ACLF. The disturbances
in hepatic haemodynamics in alcohol-related ACLF have been
found to associate with inﬂammation, multiorgan failure and
marked activation of the sympathetic nervous system, supporting
a speciﬁc role of alcohol in the development of HE, both in
alcohol-related decompensation or alcohol-induced ACLF [51].
The GABA system
The potential role of c-aminobutyric acid-(GABA) or glutamate-
mediated neurotransmission in the pathophysiology of HE,440 Journal of Hepatology 201together with roles for neurosteroids or endogenous benzodiaze-
pines or other neurotransmitters like serotonin, dopamine,
adenosine and histamine have been recently revised [52]. The
high complexity of brain circuitries, controlled by multiples types
of GABAergic interneurons and the large variety of GABA-A
receptors precluded deﬁning a more clear and speciﬁc role of
GABA on HE [53].
Genetic factors
The human glutaminase gene (OMIM: 138280) is located on
chromosome 2 (2q32-q34) [54]. In a prospective study (109
patients with cirrhosis in the estimation cohort, 177 patients in
the validation cohort, and 107 healthy controls), Romero-Gómez
et al. identiﬁed a microsatellite in the promoter region of the glu-
taminase gene (kidney type) containing between 8 and 29 GCA
repeats. The longest microsatellite correlated with higher gluta-
minase activity in vivo. It increased the risk for overt HE in
cirrhotic patients from 20% to 40% (hazard ratio 3.12 [CI: 1.39–
7.02]; p = 0.006) [55]. Furthermore, they carried out a functional
analysis that showed how longer forms of the microsatellite
repeat promoted higher activity in vitro, which may increase
ammonia production [56]. Therefore, the authors concluded that
this genetic difference in the conversion rate of glutamine to
ammonia, possibly explained at least in part the variability in
the clinical presentation of HE (Fig. 3). Mayer et al. conﬁrmed
these results in a cohort of 158 patients with liver cirrhosis.
The long-long homozygous form (also called major homozygous)
was independently associated with HE [57].Diagnosis and differential diagnosis of hepatic
encephalopathy
Deﬁnitions and general issues
HE is characterized by a wide spectrum of nonspeciﬁc neurolog-
ical and psychiatric abnormalities [58]. In order for such abnor-
malities to be qualiﬁed as HE one should: (1) conﬁrm that the
degree of hepatic failure and/or portal-systemic shunting is
severe enough to be able to cause HE, and (2) exclude other
causes of neurological and psychiatric dysfunction. Basic as it
may seem, this diagnostic procedure is neither routine nor neces-
sarily straightforward. In relation to point 1, measurement of
fasting ammonia levels is a reasonable start, because the absence
of hyperammonemia makes it extremely unlikely that the
observed neuropsychiatric abnormalities are due to HE. There-
fore, ﬁnding normal ammonia levels in a confused, disorientated
or comatose cirrhotic patient should prompt immediate search
for alternative causes of neuropsychiatric dysfunction. Point 2 is
more complicated, because patients with end-stage liver disease
are prone to several types of metabolic encephalopathy (for
example uremic and nutritional encephalopathy), and also to
non-metabolic neuropsychiatric dysfunction (for example
alcohol-related dementia and cerebrovascular disease). These
can obviously co-exist with HE, somewhat hampering the
‘exclusion diagnosis’ procedure [59]. In addition, two common
complications of end-stage liver disease, hyponatremia and
inﬂammation/infection, are capable of causing neuropsychiatric
dysfunction in the absence of cirrhosis. However, they have also
been convincingly shown to act synergistically with gut-derived
neurotoxins in determining neuropsychiatric dysfunction in
experimental models of HE and in the clinical setting5 vol. 62 j 437–447
Table 1. Diagnosis and differential diagnosis of hepatic encephalopathy (HE).
STEP 1 STEP 2
Confirm that the degree of hepatic failure and/or 
portal-systemic shunt is severe enough 
Exclude other causes of neurological and/or psychiatric dysfunction 
Debated 
issues 
• Border between hepatic and hyponatremic/septic 
encephalopathies
• Neurological and/or psychiatric comorbidity 
Practical 
suggestions 
• Standard indices of hepatic failure (Child-Pugh, 
MELD scores)
• Confirmation of the presence/absence of 
significant portal-systemic shunt
• Neuropsychiatric profiling (please refer to text). Structured 
questions aimed at assessing orientation to time/space. Glasgow 
Coma Scale for uncooperative patients
• Simple but quantitative nutritional assessment and estimate of 
recent dietary and fluid intake
• History taking, aimed at identifying obvious precipitants and 
previous episodes of HE, especially if requiring hospitalisation 
• Full blood count, liver/kidney function, electrolytes, ammonia, 
TSH, CRP, glycaemia, vitamin B12 and urine analysis
• Cerebral imaging should be performed if the clinical profile is 
unusual, the onset of symptoms is abrupt/severe, if there are focal 
neurological signs and limited or no response to treatment
• Evaluation of the response to treatment (of the precipitant and/or 
ammonia-lowering strategies) 
JOURNAL OF HEPATOLOGY[19,60,61]. For example, cognitive impairment (overt or subclin-
ical) has been documented in 42% of patients with cirrhosis with-
out infection, in 79% of those with infection and in 90% of those
with sepsis [19]. Thus, in patients with cirrhosis, the pathophys-
iological and clinical borders between hepatic and hyponatremic/
septic encephalopathy may be less obvious than in healthy or
other disease controls. In addition, in everyday practice it is rea-
sonable and routine to treat them simultaneously. By contrast,
one should be absolutely clear that neuropsychiatric abnormali-
ties, related to hypoglycaemia, hypothyroidism, hypoxia, the
desired or undesired effects of drugs, such as opioids or benzodi-
azepines should be qualiﬁed as such and not as HE, even when
they occur in cirrhotic patients [62]. Differential diagnosis is
crucial for two reasons: (i) the encephalopathy we refer to in
order to deﬁne ALF or ACLF needs to be hepatic encephalopathy;
(ii) the wrong attribution of neurological/psychiatric symptoms
to HE might prevent the diagnosis and the correct management
of other causes of neuropsychiatric dysfunction, which are
unlikely to beneﬁt from ammonia-lowering drugs or from
transplantation. Multiple underlying mechanisms of altered
mental status in a patient with cirrhosis should be sought for
and treated individually.
In order to tackle these diagnostic issues, it may be useful to
draw suggestions from the more general literature. From a
psychiatric perspective, episodic overt HE can be classiﬁed as a
delirium [63], an etiologically nonspeciﬁc syndrome, character-
ized by disturbances in cognition and consciousness, develop-
ment over a short period time, and ﬂuctuation over time [64].
Delirium is common in hospitalized and critically ill patients.
Within this context, its pathophysiology is largely unknown,
and generally assumed to be mixed [65]. Interestingly, a recent
review on delirium in the ICU does not indicate that efforts are,
or should be made to establish the pathophysiology of a delirium
episode [65]. It follows that treatment is empirical rather than
aetiological [66]. Exactly as it happens with HE, it has also been
estimated that non-speciﬁcally trained staff can miss theJournal of Hepatology 201diagnosis of delirium in almost 70% of cases [67]. Efforts have
recently been directed towards the prediction of delirium. A large
study by van den Boogaard and co-workers deﬁnes the likelihood
of developing delirium in the ICU based on 10 risk factors that are
readily available within 24 h of admission: age, APACHE-II,
urgent admission category, infection, coma, sedation, morphine
use, urea level and metabolic acidosis [68]. This kind of research
seems well directed, because a diagnosis of delirium has been
associated with increased mortality [69] and also with impaired
long-term cognitive performance [70].
Practical diagnostic recommendations
Despite the highlighted difﬁculties, some practical recommenda-
tions for the diagnosis of overt HE in a hospitalized cirrhotic
patient can be formulated (Table 1).
Clinical features and clinical scales
Albeit non-speciﬁc, there is a neuropsychological proﬁle to HE
type A. Patients with mild overt HE may be inappropriate and
euphoric, but higher grades tend to be almost invariably charac-
terized by slowness (in mentation, motion and verbal produc-
tion), disorientation, the presence of ﬂapping tremor, excessive
daytime sleepiness, all the way to lethargy and coma. Focal neu-
rological signs are rare while bilateral Babinski may be observed.
Obvious extrapyramidal signs and hepatic myelopathy are also
rare but should be considered, especially in male patients with
documented large shunts and a history of multiple, severe epi-
sodes of HE [71]. While the patient is still awake and cooperative,
verbal abilities tend to be preserved, thus obtainment of substan-
tially adequate answers to simple questions (‘Good morning, how
are you today?’) may lead to false reassurance. In contrast,
questions should be aimed at speciﬁcally assessing orientation
to time and space, possibly in a structured fashion [72,73]. Scales,
such as CHESS and the Modiﬁed-orientation log have been5 vol. 62 j 437–447 441
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suggested to be useful in this respect [74]. Recording of the
results of such evaluations in the notes may simplify monitoring,
also across different nurses/physicians and over subsequent
shifts. If the patient is not cooperative, the Glasgow Coma Scale
should be utilized both at baseline and over the subsequent
monitoring phases [75].
History taking and patient proﬁling
History taking from cooperative patients or from relatives/care-
givers should be aimed at identifying obvious precipitants such
as constipation, symptoms of chest, urinary tract or other infec-
tions, gastro-intestinal bleeding and dehydration. If identiﬁed,
these should be corrected. A history of previous episodes of HE,
especially if requiring hospitalization, increases the likelihood
of the current episode being due to HE and should be recorded.
Finally, it should be taken into account that HE associated with
ACLF tends to occur in younger cirrhotics with alcohol-related
disease and a systemic inﬂammatory reaction, bacterial infec-
tions, active alcohol misuse and/or dilutional hyponatremia [6].Laboratory tests
A panel of laboratory tests to include full blood count, liver and
kidney function, electrolytes, ammonia, TSH, CRP, vitamin B12
and a urine analysis should always be obtained, and abnormali-
ties, such as anaemia, hypo/hyperglycemia or hyponatremia
should be corrected. Active alcohol misusers can be considered
thiamine/vitamin deﬁcient by default and supplemented.
Ammonia, given its central pathogenic role and known prob-
lems with its measurement, deserves further comment. There is
probably limited advantage in measuring arterial compared to
venous ammonia levels, which can be considered acceptable
[76,77]. Venous blood should be preferably drawn when the
patients is fasting, in a tube with a stabiliser, refrigerated on
ice, sent to the lab immediately and analysed immediately. If
arterial or capillary ammonia are utilized, the appropriate refer-
ence values should be obtained and utilized. Capillary ammonia
is best measured on blood obtained from the earlobe, as sweat
artefact leads to signiﬁcant overestimation on blood drawn from
the ﬁngertip [78,79]. Finally, it should be noted that ammonia
measurements are problematic in terms of false positives and
not false negatives, thus the exclusion of HE based on normal
ammonia levels is unlikely to be fraught by measurement issues.
Along these same lines, the recently published joint EASL/AASLD
guidelines suggest that if ammonia levels are normal the diag-
nosis of HE is in question. In addition, they warn against the
use of high ammonia levels alone for the purpose of diagnosing,
staging and formulating prognosis [80].Imaging
Cerebral imaging should be performed if the clinical proﬁle is
unusual, if the onset of the symptoms is abrupt and severe, if
there are focal neurological signs and if there is limited or no
response to treatment of the precipitant and/or to ammonia-low-
ering strategies. In most routine, practical conditions, a brain CT
without contrast is sufﬁcient, as it allows to diagnose/rule out
cerebral and subdural haemorrhage. Structural MRI is probably
more appropriate to better deﬁne dementia-like, prolonged442 Journal of Hepatology 201confusional states and to diagnose/rule out encephalitis and
Wernicke’s disease.
Neurophysiological tools
The EEG, although non-speciﬁc, provides information on the
severity of HE in both cooperative and uncooperative patients,
it may be useful to monitor them and may help for the inclusion
of HE in indices aimed at transplant selection procedures [81].
The grading of the severity of EEG alterations in HE can be based
on visual pattern recognition, which has limited reliability and
reproducibility, on semi-quantitative evaluation of the frequency,
or on automated, spectral analysis of the digitalized tracing. Spec-
tral analysis is more accurate and less operator-dependent. Its
value was recently conﬁrmed [82] and a large, validated observa-
tional study suggests that the addition of a spectrally derived EEG
index improves the predictive value of MELD. The EEG can be
recorded at any stage of the patient’s evolution, and it can be
used to monitor the severity of HE over time and the response
to treatment in an objective fashion, regardless of patient
cooperation. As sedation, psychoactive drugs and hypothermia
can produce EEG alterations not unlike those, which characterize
HE, these should be considered as confounders in the diagnostic
process. In severe coma, combinations of sensory evoked
potential indices can contain information on residual cortical or
sub-cortical activity [83]. Neurophysiological monitoring of HE
due to acute liver failure would seem reasonable but experience
is limited.
Response to treatment
Unless contraindicated, an attempt at non-aggressive bowel
cleansing and/or ammonia-lowering treatment can be considered
part of the diagnostic armamentarium. A neuropsychiatric syn-
drome that responds to ammonia-lowering strategies is likely
to be HE.Management of hepatic encephalopathy in a hospitalized
cirrhotic patient
Treatment of the acute episode
General measures and monitoring
Early risk stratiﬁcation of patients with HE is required. This may
be performed using the CLIF organ failure scoring system to
determine whether the patient has ACLF or not [5]. If a patient
has ACLF and associated HE, then he should be managed in an
intensive care unit. Detailed description of organ support is out-
side the scope of this article and has been reviewed elsewhere
[84]. The role of monitoring ammonia levels, jugular venous
oxygen saturation, evoked potentials, EEG or intracranial pres-
sure remains unascertained.
Airway, breathing, and circulation. Admission to the intensive care
unit for close monitoring and airway protection should be consid-
ered in all patients with overt HE but particularly if this is asso-
ciated with ACLF or if the airway is considered to be at risk. Short
acting drugs should be used for sedation if needed because
benzodiazepines can stay in the circulation for a long time.
Hypercapnia and hypoxia should be avoided as they may
alter cerebral blood ﬂow. Supplemental oxygen or mechanical5 vol. 62 j 437–447
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ventilation should be used as required. Inotropes should be used
to maintain mean arterial pressure to ensure adequate cerebral
perfusion [85].
Role of the precipitating event. Although the prevalence of a pre-
cipitating event is more common in patients with ACLF compared
to those without, in about 40% patients no precipitating event
was found [6]. The most common causes were the use of diuretics
suggesting intravascular volume depletion, bacterial infection
and alcohol binge. Gastro-intestinal bleeding, as a precipitating
event, was under-represented in patients with HE. Any identiﬁ-
able precipitating event should be promptly treated, cultures
performed from multiple sites and, appropriate and early
antibiotics should be administered (Fig. 4).
Glucose, nutrition, and electrolytes. Hypoglycemia should be cor-
rected and patients monitored to prevent further hypoglycemic
episodes. Hyperglycemia should be prevented as this can make
brain swelling worse but there is no evidence for a tight control
of glucose [84]. Hyponatremia should be prevented by infusion
of crystalloids as this can lead to worsening of HE. Hypernatremia
can lead to cellular dysfunction and should be prevented. Vita-
mins, particularly thiamine should be administered to patients
with underlying alcoholic liver disease to prevent occurrence of
Wernicke’s encephalopathy, particularly when glucose contain-
ing ﬂuids are administered. Low protein diets have not beenHE con
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Journal of Hepatology 201shown to prevent recovery from HE and should be avoided as this
can lead to protein breakdown. A restricted protein diet was com-
pared with normal protein diet, which showed that the wake-up
rate for the patients in both groups was similar but increased
protein breakdown was observed in patients treated with a low
protein diet [86]. A detailed guidance on the nutritional
management of patients with HE was recently published [87].Speciﬁc
Ammonia .Ammonia, a physiologic product of the intermediary
metabolism, is composed of nitrogen and hydrogen. The human
body has several sources of ammonia: (a) glutamine deamidation
by glutaminase (GLS) in the small intestine; (b) urea and nitrog-
enous compound hydrolysis by gut bacteria [88]; (c) ammonia
production and excretion in the kidneys. In the healthy state,
hepatic metabolism of ammonia takes place in two areas: (1) in
periportal hepatocytes, through the urea cycle (the most
important pathway); (2) in pericentral hepatocytes, transforming
small quantities of ammonia into glutamine through the action of
glutamine synthase [89]. In cirrhosis or in the presence of porto-
systemic shunts, the liver is by-passed and ammonia detoxiﬁca-
tion takes place in the muscle through glutamine synthesis by
glutamine synthetase [90]. Furthermore, the kidney is an organ
capable of synthesizing and degrading ammonia, depending upon
the clinical situation [91,92].firmed 
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+
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At present there is no drug that has been consistently shown to
reduce ammonia by targeting its metabolism in hospitalized cir-
rhotic patients. Some new approaches to treat hyperammonemia
combine potential ammonia-lowering agents together with prod-
ucts able to promote glutamine excretion. Ornithine phenylace-
tate (OP) is a drug that stimulates hepatic and muscle glutamine
synthesis through the action of ornithine and traps ammonia in
form of glutamine, which is then removed following conjugation
with phenylacetate [93]. In an open-label study, OP was shown
to prevent the rise in ammonia concentration in cirrhotic patients
presenting with a gastro-intestinal bleed [94]. A randomized
study is underway. Another interesting approach that has not
been tested in this population is a drug that has been used to treat
urea cycle enzyme disorders, glycerol phenylbutyrate. This com-
pound acts by scavenging glutamine, a precursor of ammonia
and was shown to be useful in the secondary prophylaxis of HE
in a phase 2b study [95]. Furthermore, L-ornithine-L-aspartate
was found superior to placebo improving neuropsychiatric
alterations and decreasing ammonia levels in a meta-analysis.
The analysis omitted the results of some studies [96].Targeting the gut. The mainstay of therapy of a hospitalized
patient with cirrhosis is lactulose, which acts by reducing the
absorption of ammonia by converting it to ammonium in the
colon. It has recently been shown to prevent the occurrence of
HE in patients with a gastrointestinal bleed [97]. There is a lack
of good data comparing lactulose against placebo in patients with
advanced HE [98], but this approach remains to be thoroughly
tested in clinical trials. The administration of enemas to clear
the bowel is a useful adjunct to lactulose but the frequency of
administration; type of enema to be used and clinical efﬁcacy
need to be better deﬁned. A major advance in the management
of HE was the introduction of rifaximin, a non-absorbable antibi-
otic. While its use has been conﬁrmed in the secondary prophy-
laxis of HE [99], its role in the management of the hospitalized
cirrhotic remains to be validated. A special population of patients
are those undergoing insertion of a transjugular intrahepatic por-
tosystemic stent-shunt. A randomized study comparing lactulose,
rifaximin and placebo were unable to conﬁrm the beneﬁt of any
these approaches to prevent the occurrence of HE [100].
Albumin and albumin dialysis. Albumin is more than just a volume
expander and may have important detoxiﬁcation properties,
modulating inﬂammatory response and endothelial function
[101]. In an early controlled study, the potential role of albumin
in HE was observed in patients with diuretic-related HE [102].
This approach was tested in a randomized controlled clinical trial
[103], which found that although there was no signiﬁcant differ-
ence in the resolution of HE between the groups, survival was
enhanced in the albumin group, suggesting that the trial was
underpowered. The potential beneﬁcial effects of albumin were
translated into studies where the patient’s plasma was dialysed
against albumin using the molecular adsorbent recirculating Sys-
tem (MARS). In an early randomized study, a beneﬁcial effect on
HE was observed without any signiﬁcant effects on ammonia
[104]. These observations were conﬁrmed in a large randomized,
multicentre clinical trial, showing incontrovertibly that those
patients, not responding to the best standard of care, had signif-
icant improvement in HE and time to reduction in severity, when
treated with MARS [105]. These observations were conﬁrmed in a
multicentre randomized clinical trial in patients with ACLF, the444 Journal of Hepatology 201RELIEF trial [106]. Although overall survival was not improved,
a signiﬁcant effect on HE was observed in a subgroup analysis.
The role of benzodiazepine antagonists. Flumazenil, a benzodiaze-
pine receptor antagonist has been trialled in patients with HE
based upon the concept that endogenous benzodiazepines may
contribute to hepatic encephalopathy. The data suggest that this
approach is safe and may be particularly relevant in patients with
HE related to iatrogenic administration of benzodiazepines. A fur-
ther limitation is the short half-life of the drug [107].
Embolization of portacaval shunts. One of the main contributors to
the development of HE is portacaval shunting. Large spontaneous
portacaval shunts, usually present with persistent HE, can result
in hospital admission with advanced coma. In some patients with
HE, large spontaneous shunts that are accessible to embolization,
may beneﬁt. In a retrospective cohort study this approach was
shown to be of beneﬁt in about 70% of patients, particularly if
their MELD score was 11 or less [108]. These data were conﬁrmed
in another retrospective controlled clinical study [109]. Random-
ized controlled data are not available and it is clear that many
patients will not beneﬁt and also have portal hypertension
related complications. Therefore, patient selection is extremely
important.
TIPSS-related hepatic encephalopathy. De novo HE can affect up to
30–50% of patients who undergo TIPSS [110] and this can some-
times be severe enough to result in cerebral oedema and coma
[111]. The mechanism of this is complex and related to a combi-
nation of hyperammonemia, increased portosystemic shunting
with resultant endotoxemia, and alterations in cerebral blood
ﬂow [112]. Treatment options are limited and a randomized trial
of lactulose or rifaximin, used prophylactically, was not shown to
be useful [100]. Patients with troublesome HE after TIPSS respond
well to shunt occlusion, which remains the therapy of choice
[113].
Role of liver transplantation
A hospitalized, critically ill cirrhotic patient with HE should be
worked up from a transplant perspective. Transplantation itself
and subsequent immunosuppressant treatment are risk factors
for both neurological and psychiatric dysfunction, in the immedi-
ate and long-term post-transplant period, respectively [64].
Patients that are transplanted with severe multiorgan failure,
including severe HE, can have a good outcome with liver trans-
plantation. Over 85% mortality was observed in patients with 3
or more organ failures without liver transplantation. This was
reduced to a mortality of 20% with early liver transplantation
[5]. However, at present there is no priority for severe HE patients
on the waiting list for transplantation where organ allocation is
based on the MELD score, which underestimates the risk of death
[80]. A new scoring system has been developed and validated by
the CLIF consortium, which needs further evaluation before it can
be implemented for the clinical allocation of organs [114].Conclusions
In conclusion, HE in a hospitalized patient, particularly when it is
associated with ACLF, is associated with a high mortality rate
independent of other organ failures. The mechanism of HE in5 vol. 62 j 437–447
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ACLF is not clear but cerebral oedema affects a relatively small
group of patients and although ammonia is important, the sys-
temic inﬂammatory response plays an important part. Glutamin-
ase gene alterations seem to modulate the HE risk and may allow
selection of patients for prophylaxis. Treatment options are lim-
ited. It is clear that HE in ACLF patients is distinct clinically, prog-
nostically and pathophysiologically to the conventional forms
represented in type A, B and C. If the current observations are
borne out by other ongoing studies, then it should perhaps be
classiﬁed into a separate group, type D.Conﬂict of interest
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